Impact of KRAS mutation status on the efficacy of immunotherapy in lung cancer brain metastases

Impact of KRAS mutation status on the efficacy of immunotherapy in lung cancer brain metastases

Abstract Immune checkpoint inhibitors (ICIs) have resulted in improved outcomes in non-small cell lung cancer (NSCLC) patients. However, data demonstrating the efficacy of ICIs in NSCLC brain metastases (NSCLCBM) is limited. We analyzed overall survival (OS) in patients with NSCLCBM treated with ICI...

Full description

Bibliographic Details
Main Authors: Adam Lauko, Rupesh Kotecha, Addison Barnett, Hong Li, Vineeth Tatineni, Assad Ali, Pradnya Patil, Alireza M. Mohammadi, Samuel T. Chao, Erin S. Murphy, Lilyana Angelov, John H. Suh, Gene H. Barnett, Nathan A. Pennell, Manmeet S. Ahluwalia
Format: Article
Language:English
Published: Nature Publishing Group 2021-09-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-021-97566-z

Internet

https://doi.org/10.1038/s41598-021-97566-z

Similar Items